Innoviva (INVA) Projected to Post Quarterly Earnings on Wednesday

Innoviva (NASDAQ:INVA - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $87.10 million for the quarter.

Innoviva (NASDAQ:INVA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter. Innoviva had a negative net margin of 16.15% and a positive return on equity of 15.77%. The firm had revenue of $88.63 million for the quarter. On average, analysts expect Innoviva to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Innoviva Stock Down 1.1%

NASDAQ INVA traded down $0.20 during trading hours on Friday, hitting $18.72. 885,574 shares of the company were exchanged, compared to its average volume of 903,609. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 0.40. Innoviva has a 52-week low of $16.67 and a 52-week high of $22.00. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -18.53 and a beta of 0.37. The company has a 50 day moving average of $19.99 and a two-hundred day moving average of $18.72.

Analyst Ratings Changes

Several equities analysts have issued reports on INVA shares. Cantor Fitzgerald initiated coverage on shares of Innoviva in a research note on Friday, July 11th. They issued an "overweight" rating and a $26.00 price objective for the company. Wall Street Zen raised shares of Innoviva from a "hold" rating to a "buy" rating in a research note on Wednesday, April 30th. Finally, HC Wainwright began coverage on Innoviva in a research note on Monday, July 14th. They set a "buy" rating and a $40.00 target price for the company.

Hedge Funds Weigh In On Innoviva

Several hedge funds have recently bought and sold shares of INVA. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Innoviva by 21.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 171,116 shares of the biotechnology company's stock valued at $3,102,000 after acquiring an additional 30,792 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Innoviva by 17.8% in the 1st quarter. AQR Capital Management LLC now owns 167,456 shares of the biotechnology company's stock valued at $3,036,000 after purchasing an additional 25,317 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Innoviva by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,882 shares of the biotechnology company's stock worth $596,000 after purchasing an additional 1,392 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Innoviva by 81.1% during the first quarter. Royal Bank of Canada now owns 21,530 shares of the biotechnology company's stock worth $389,000 after buying an additional 9,639 shares in the last quarter. Finally, NewEdge Advisors LLC purchased a new stake in shares of Innoviva during the first quarter worth about $243,000. Hedge funds and other institutional investors own 99.12% of the company's stock.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.